ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Analyst Ratings
USA - NASDAQ:ADPT - US00650F1093 - Common Stock
16.8 USD
-0.1 (-0.59%)
17 USD
+0.2 (+1.19%)
ChartMill assigns a Buy % Consensus number of 84% to ADPT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 14.28. This target is -15% below the current price.
ADPT was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ADPT.
In the previous month the buy percentage consensus was at a similar level.
ADPT was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-22 | BTIG | Maintains | Buy -> Buy |
| 2025-10-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-13 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-09-30 | Guggenheim | Initiate | Buy |
| 2025-08-06 | TD Cowen | Maintains | Buy -> Buy |
| 2025-08-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-06-18 | Craig-Hallum | Initiate | Buy |
| 2025-05-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-02 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-21 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2025-02-20 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-02-13 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-01-28 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-12-18 | BTIG | Maintains | Buy -> Buy |
| 2024-11-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-10-02 | BTIG | Maintains | Buy -> Buy |
| 2024-08-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-04 | BTIG | Maintains | Buy -> Buy |
| 2024-02-16 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-15 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-11-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-10-24 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-10-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-04 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-05 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-02-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-02-15 | Credit Suisse | Reiterate | Underperform |
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
What do analysts expect the price target to be for ADAPTIVE BIOTECHNOLOGIES (ADPT)?
14 analysts have analysed ADPT and the average price target is 14.28 USD. This implies a price decrease of -15% is expected in the next year compared to the current price of 16.8.
What is the consensus rating for ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?
The consensus rating for ADAPTIVE BIOTECHNOLOGIES (ADPT) is 84.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for ADAPTIVE BIOTECHNOLOGIES stock?
The number of analysts covering ADAPTIVE BIOTECHNOLOGIES (ADPT) is 14.